Search
Lilly's Oral SERD Imlunestrant Seeks Marketing Approval in China for Advanced Breast Cancer Treatment
2025-04-09 /
Read about 0 minute
Author：小编
Lilly's orally administered selective estrogen receptor degrader (SERD), Imlunestrant tablet, has garnered marketing approval from China's National Medical Products Administration (NMPA). This innovative drug is specifically designed for patients with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. The Phase 3 clinical trial of Imlunestrant has yielded promising results, demonstrating its ability to consistently inhibit ER activity regardless of the ESR1 mutation status. This advancement could potentially pave the way for a novel treatment option benefiting approximately 70% of patients with ER+ breast cancer.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
